University of Leicester nets $3.6M grant for protein drug-target work; pSivida begins PhIII eye implant trial;

> The University of Leicester corralled a £2.4 million ($3.6 million) research funding grant for its work on gene expression that could lead to anti-cancer drugs using protein complexes as drug targets. Report

> pSivida ($PSDV) began a Phase III pivotal trial, the first of two, for its micro-insert designed to treat chronic, non-infectious uveitis affecting the posterior segment of the eye. Release

> Researchers at RMIT in Australia have created nanoparticles called yoctowells that allow for better encapsulation of drugs and controlled release. Story

> Oxford professor Constantin Coussios is looking into the potential of ultrasound as a drug-delivery tool, most particularly for people with vertebrae problems. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.